Online citations, reference lists, and bibliographies.
← Back to Search

Hepatocellular Carcinoma Targeting Effect Of PEGylated Liposomes Modified With Lactoferrin.

Minyan Wei, Yuehong Xu, Qi Zou, Liuxiao Tu, Chenyi Tang, T. Xu, Lihe Deng, C. Wu
Published 2012 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
A hepatocellular carcinoma targeting lactoferrin (Lf) modified PEGylated liposome system was developed for improving drug efficacies to hepatic cancer cells. In this present work, PEGylated liposomes (PLS) were successfully prepared by the thin film hydration method combined with peglipid post insertion. Lf was covalently conjugated to the distal end of DSPE-PEG2000-COOH lipid by amide bound and loaded onto PEGylated liposomes surface as the targeting ligand. To confirm the targeting efficacies to hepatic cancer, coumarin-6 and DiR were encapsulated as fluorescent probes. The confocal microscopy and flow cytometry demonstrated that Lf conjugated PEGylated liposomes (Lf-PLS) were efficiently associated by HepG2 cells, while limited interaction was found for liposomes modified with a negative control protein. A similar pharmacokinetic behavior was observed in pharmacokinetics study of the liposomal formulations. Meanwhile, the in vivo imaging of liposomes in HepG2 tumor bearing mice indicated that Lf-PLS achieved more accumulation in tumor compared with PLS without Lf conjugated. The significant in vitro and in vivo results suggested that Lf-PLS might be a promising drug delivery system for hepatocellular carcinoma therapy with low toxicity.
This paper references
10.1007/S00018-005-5371-1
Mammalian lactoferrin receptors: structure and function.
Y. Suzuki (2005)
10.1139/O01-214
Lactoferrin and host defense.
P. Ward (2002)
10.1016/0169-409X(93)90046-7
Nano- and microparticles for the delivery of polypeptides and proteins
P. Couvreur (1993)
10.1016/j.ijpharm.2010.03.004
Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Chun Lei Li (2010)
10.1016/j.jconrel.2011.03.014
Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Y. Xiang (2011)
10.1016/J.TIV.2006.10.007
In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells.
M. Davoren (2007)
10.1016/J.EJPB.2004.12.009
Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy.
S. Anabousi (2005)
10.1016/0014-5793(96)00452-8
Insertion of poly(ethylene glycol) derivatized phospholipid into pre‐formed liposomes results in prolonged in vivo circulation time
P. S. Uster (1996)
10.1016/j.ejps.2010.04.004
Lactosaminated human albumin, a hepatotropic carrier of drugs.
L. Fiume (2010)
10.1007/S00018-005-5366-Y
Lactoferrin: a multi-tasking protein par excellence.
E. Baker (2005)
10.1016/j.ijpharm.2010.08.005
Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8.
A. Bicho (2010)
10.1016/j.ejps.2011.05.007
Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin.
T. J. Evjen (2011)
Plasma clearance and liver uptake of chylomicron remnants generated by hepatic lipase lipolysis: evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway.
S. Crawford (1999)
10.1016/J.JCONREL.2007.11.002
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles.
Shyh-Dar Li (2008)
10.1042/0264-6021:3480113
Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor's lectin properties.
D. Mcabee (2000)
10.1016/S0014-5793(99)01320-4
A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs
T. Ishida (1999)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1016/j.biomaterials.2009.09.103
The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model.
Zhenghong Xu (2010)
10.1021/BI963078U
Identification and isolation of a 45-kDa calcium-dependent lactoferrin receptor from rat hepatocytes.
D. J. Bennatt (1997)
10.1016/j.ijpharm.2009.05.013
pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
P. Simard (2009)
10.1016/j.ejps.2010.03.007
Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery.
H. Chen (2010)
10.1016/j.biomaterials.2010.09.024
Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo.
H. Xie (2011)
10.1016/0014-5793(95)00082-K
Removal of lactoferrin from plasma is mediated by binding to low density lipoprotein receptor‐related protein/α 2‐macroglobulin receptor and transport to endosomes
M. Meilinger (1995)
10.1007/978-1-4757-9068-9_14
Identification and Analysis of a Ca2+-Dependent Lactoferrin Receptor in Rat Liver
D. Mcabee (1998)
10.1016/j.metabol.2010.08.013
Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
J. H. Moon (2011)
Identification and analysis of a CA(2+)-dependent lactoferrin receptor in rat liver. Lactoferrin binds to the asialoglycoprotein receptor in a galactose-independent manner.
D. Mcabee (1998)
10.1016/j.ijpharm.2009.07.014
Disaccharide-modified liposomes and their in vitro intracellular uptake.
C. K. Song (2009)
10.1021/BC0602782
Protein-liposome conjugates using cysteine-lipids and native chemical ligation.
Sanne W. A. Reulen (2007)
10.1021/NL047996M
Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles.
C. Kirchner (2005)
10.1517/13543784.16.9.1391
Early experience with novel immunomodulators for cancer treatment
Z. Thotathil (2007)
10.1016/j.bbamem.2009.06.022
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer.
Shyh-Dar Li (2009)
10.1016/j.jconrel.2009.06.024
A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
J. Mai (2009)
10.1016/J.PLIPRES.2004.12.001
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
T. Andresen (2005)
10.1023/A:1020178304031
Biophysical Aspects of Using Liposomes as Delivery Vehicles
A. Ulrich (2002)
10.1016/S0005-2736(01)00357-1
In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.
D. Iden (2001)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1016/j.jconrel.2008.10.018
Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
A. Abu-Lila (2009)
10.1016/j.ijpharm.2009.01.023
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
X. Li (2009)
10.1016/J.ADDR.2004.01.011
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
10.1016/J.BIOMATERIALS.2007.09.024
The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain.
R. Huang (2008)
10.1016/S1043-2760(01)00526-4
Diverse roles for the LDL receptor family
D. Strickland (2002)
10.1016/S0168-3659(02)00006-8
Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers.
P. Opanasopit (2002)
10.1016/j.ejps.2011.05.010
Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: effect of monensin intercalated into folate-tagged liposomes.
N. Tyagi (2011)
10.1016/j.ijpharm.2010.09.012
Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting.
Swati A. Guhagarkar (2010)
10.1245/s10434-007-9705-0
Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy
M. Thomas (2007)
10.1021/BI963079M
Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner.
D. J. Bennatt (1997)
10.1016/S0168-3659(01)00315-7
Tumor targeting using anti-her2 immunoliposomes.
J. Park (2001)
10.1016/J.JCONREL.2004.07.033
Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
N. Maeda (2004)
10.1016/j.jconrel.2011.02.015
Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer.
Ronak Savla (2011)
10.2147/IJN.S2263
Nano-vectors for efficient liver specific gene transfer
A. Pathak (2008)
10.1002/cmmi.266
Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes.
H. M. H. F. Sanders (2009)
10.1021/bc900369d
Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers.
S. Salmaso (2009)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
10.1016/j.ejps.2009.07.002
Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study.
Shuhua Bai (2009)
10.1016/j.jconrel.2009.09.020
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
X. Ying (2010)
10.1073/pnas.0435906100
Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes
V. Torchilin (2003)
10.1016/j.jconrel.2010.03.015
Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
M. Loi (2010)
10.1016/j.ijpharm.2009.03.018
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Jie Gao (2009)
10.1016/S0305-7372(02)00123-8
Treatment of hepatocellular carcinoma: is there an optimal strategy?
M. Varela (2003)
10.1016/J.EJPS.2007.05.113
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
T. Elbayoumi (2007)
10.1016/j.ejps.2008.08.008
In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors.
A. Jain (2008)
10.1038/emm.1997.16
Lactoferrin as a gene delivery vehicle to hepatocytes
S. T. Oh (1997)
10.1016/s0021-9258(18)54329-5
Binding and endocytosis of apo- and holo-lactoferrin by isolated rat hepatocytes.
D. McAbee (1991)
10.1016/J.EJPS.2006.07.004
In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer.
S. Anabousi (2006)
10.1016/j.jconrel.2008.10.016
Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations.
Kai-li Hu (2009)
10.1016/j.biomaterials.2008.09.014
The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.
Zhenghong Xu (2009)
10.1111/j.1471-4159.2008.05628.x
Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation
Y. Iwamaru (2008)
10.1016/S0928-0987(00)00088-9
X-ray crystallographic characterization of nilvadipine monohydrate and its phase transition behavior.
F. Hirayama (2000)
10.1158/1078-0432.CCR-05-1895
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
W. Zamboni (2005)



This paper is referenced by
10.1002/ijc.30517
Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities
N. Mohamed (2017)
10.1186/s12885-016-2870-4
Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer
Hongxia Ye (2016)
10.1016/j.ejpb.2015.01.030
Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
H. Xu (2015)
10.1016/j.colsurfb.2015.03.046
RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Minglu Chang (2015)
10.3109/10242422.2015.1053469
Optimization of lipase-catalyzed synthesis of novel galactosyl ligands for selective targeting of liposomes to the asialoglycoprotein receptor
H. Nie (2015)
10.1016/j.ijpharm.2015.05.047
Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor.
J. Chen (2015)
10.1016/j.ijpharm.2013.06.006
Protein entrapment in PEGylated lipid nanoparticles.
A. Angelova (2013)
10.1016/J.CCLET.2015.01.005
Lipase-catalyzed synthesis of novel galactosylated cholesterol
H. Nie (2015)
Nanosized systems for efficient delivery of antitumoral and anti-inflammatory drugs
R. Pireddu (2015)
10.1016/j.jconrel.2017.03.392
Protein‐lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes
Mohamed I. Gaber (2017)
10.1016/j.canlet.2012.10.007
Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
M. Shahin (2013)
10.1016/j.biopha.2015.05.008
Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Chenyang Shi (2015)
10.2147/IJN.S132472
Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin
Y. Kuo (2017)
10.1080/21691401.2018.1470525
Engineering of pectin-capped gold nanoparticles for delivery of doxorubicin to hepatocarcinoma cells: an insight into mechanism of cellular uptake
Shaivee Borker (2018)
10.1016/j.nano.2015.04.006
Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes
Li Ying Lim (2015)
CXCR 4-targeted liposomal mediated co-delivery of pirfenidone and AMD 3100 for the treatment of TGF β-induced HSC-T 6 cells activation
Aftab Ullah (2019)
10.1208/s12249-020-01829-3
In Vitro and In Vivo Evaluation of SP94 Modified Liposomes Loaded with N-14NCTDA, a Norcantharimide Derivative for Hepatocellular Carcinoma-Targeting.
Y. Jiang (2020)
10.3889/oamjms.2015.038
Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats
A. Hessin (2015)
10.1002/smll.201702037
Surface Engineering of Nanoparticles for Targeted Delivery to Hepatocellular Carcinoma.
Jingxiong Lu (2018)
10.1016/j.ijbiomac.2020.11.107
Lactoferrin coated or conjugated nanomaterials as an active targeting approach in nanomedicine.
Mona M. Agwa (2020)
10.3109/08982104.2016.1140184
Delivery of fluorescent-labeled cyclodextrin by liposomes: role of transferrin modification and phosphatidylcholine composition
J. Chen (2017)
10.4155/tde.13.6
Receptor-based targeting of therapeutics.
N. K. Mehra (2013)
10.1016/j.biomaterials.2019.119646
Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy.
Dinglin Zhang (2019)
10.3390/pharmaceutics7030255
Potential Use of Biological Proteins for Liver Failure Therapy
K. Taguchi (2015)
10.1517/17425247.2012.745848
Ceramic nanocarriers: versatile nanosystem for protein and peptide delivery
D. Singh (2013)
10.2217/nnm-2018-0134
Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma.
Mona A. Abdelmoneem (2018)
10.1080/10717544.2017.1388451
Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery
Y. Fang (2017)
10.1016/j.biomaterials.2014.03.082
Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin.
Y. Kuo (2014)
10.2217/nnm.16.37
Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.
Ketan Patel (2016)
10.1080/10717544.2018.1440666
Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12
Najla A. Altwaijry (2018)
10.1208/s12249-017-0872-4
In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen
Xiumei Gai (2017)
10.5772/54270
Polylipid Nanoparticle, a Novel Lipid-Based Vector for Liver Gene Transfer
Yahan Fan (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar